Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C

Linda E. Muñoz-Espinosa, Paula Cordero-Pérez, Eduardo Marín-López, Liliana Torres-González, Rene Malé-Velázquez, Rolando Armienta-Sarabia, María Elena Hernández-Gómez, José de Jesús Ernesto Núñez-Camarena, Marco A Olivera-Martinez, Juan Francisco Sánchez-Avila

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Aims: We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon®) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Methods: Thirty-nine patients received a 4-week induction of 5 days/week of 6 MU nIFNα plus weight-based ribavirin followed by 3 MU of nIFNα three times a week for 44 weeks. The relationship between viral response and incidence of adverse events was analyzed. Results: Early viral response (EVR) was age- and sex-dependent, with older male patients being less responsive. Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis, b) 48-week treatment and 24-week follow-up (16 patients), and c) patients with EVR (11 patients). None of the factors was significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline in younger patients and in patients aged 50 years and older. Five of 39 (13%) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27% of patients. Conclusions: nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients. Confirmation of these data in a larger population is required.

Original languageEnglish (US)
Pages (from-to)444-448
Number of pages5
JournalArchives of Medical Research
Volume44
Issue number6
DOIs
StatePublished - Aug 1 2013

Fingerprint

Hepatitis C
Genotype
Therapeutics
Asthenia
Intention to Treat Analysis
Ribavirin
Chronic Hepatitis C
Viral Load
Interferons
Weights and Measures

Keywords

  • Adverse events
  • Hepatitis C virus
  • Natural interferon alpha
  • Nonresponders
  • Sustained viral response

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Muñoz-Espinosa, L. E., Cordero-Pérez, P., Marín-López, E., Torres-González, L., Malé-Velázquez, R., Armienta-Sarabia, R., ... Sánchez-Avila, J. F. (2013). Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C. Archives of Medical Research, 44(6), 444-448. https://doi.org/10.1016/j.arcmed.2013.08.004

Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C. / Muñoz-Espinosa, Linda E.; Cordero-Pérez, Paula; Marín-López, Eduardo; Torres-González, Liliana; Malé-Velázquez, Rene; Armienta-Sarabia, Rolando; Hernández-Gómez, María Elena; Núñez-Camarena, José de Jesús Ernesto; Olivera-Martinez, Marco A; Sánchez-Avila, Juan Francisco.

In: Archives of Medical Research, Vol. 44, No. 6, 01.08.2013, p. 444-448.

Research output: Contribution to journalArticle

Muñoz-Espinosa, LE, Cordero-Pérez, P, Marín-López, E, Torres-González, L, Malé-Velázquez, R, Armienta-Sarabia, R, Hernández-Gómez, ME, Núñez-Camarena, JDJE, Olivera-Martinez, MA & Sánchez-Avila, JF 2013, 'Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C', Archives of Medical Research, vol. 44, no. 6, pp. 444-448. https://doi.org/10.1016/j.arcmed.2013.08.004
Muñoz-Espinosa LE, Cordero-Pérez P, Marín-López E, Torres-González L, Malé-Velázquez R, Armienta-Sarabia R et al. Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C. Archives of Medical Research. 2013 Aug 1;44(6):444-448. https://doi.org/10.1016/j.arcmed.2013.08.004
Muñoz-Espinosa, Linda E. ; Cordero-Pérez, Paula ; Marín-López, Eduardo ; Torres-González, Liliana ; Malé-Velázquez, Rene ; Armienta-Sarabia, Rolando ; Hernández-Gómez, María Elena ; Núñez-Camarena, José de Jesús Ernesto ; Olivera-Martinez, Marco A ; Sánchez-Avila, Juan Francisco. / Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C. In: Archives of Medical Research. 2013 ; Vol. 44, No. 6. pp. 444-448.
@article{0251de4d294b46c0803f782ca75eb4a2,
title = "Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C",
abstract = "Background and Aims: We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon{\circledR}) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Methods: Thirty-nine patients received a 4-week induction of 5 days/week of 6 MU nIFNα plus weight-based ribavirin followed by 3 MU of nIFNα three times a week for 44 weeks. The relationship between viral response and incidence of adverse events was analyzed. Results: Early viral response (EVR) was age- and sex-dependent, with older male patients being less responsive. Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis, b) 48-week treatment and 24-week follow-up (16 patients), and c) patients with EVR (11 patients). None of the factors was significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline in younger patients and in patients aged 50 years and older. Five of 39 (13{\%}) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27{\%} of patients. Conclusions: nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients. Confirmation of these data in a larger population is required.",
keywords = "Adverse events, Hepatitis C virus, Natural interferon alpha, Nonresponders, Sustained viral response",
author = "Mu{\~n}oz-Espinosa, {Linda E.} and Paula Cordero-P{\'e}rez and Eduardo Mar{\'i}n-L{\'o}pez and Liliana Torres-Gonz{\'a}lez and Rene Mal{\'e}-Vel{\'a}zquez and Rolando Armienta-Sarabia and Hern{\'a}ndez-G{\'o}mez, {Mar{\'i}a Elena} and N{\'u}{\~n}ez-Camarena, {Jos{\'e} de Jes{\'u}s Ernesto} and Olivera-Martinez, {Marco A} and S{\'a}nchez-Avila, {Juan Francisco}",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.arcmed.2013.08.004",
language = "English (US)",
volume = "44",
pages = "444--448",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C

AU - Muñoz-Espinosa, Linda E.

AU - Cordero-Pérez, Paula

AU - Marín-López, Eduardo

AU - Torres-González, Liliana

AU - Malé-Velázquez, Rene

AU - Armienta-Sarabia, Rolando

AU - Hernández-Gómez, María Elena

AU - Núñez-Camarena, José de Jesús Ernesto

AU - Olivera-Martinez, Marco A

AU - Sánchez-Avila, Juan Francisco

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background and Aims: We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon®) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Methods: Thirty-nine patients received a 4-week induction of 5 days/week of 6 MU nIFNα plus weight-based ribavirin followed by 3 MU of nIFNα three times a week for 44 weeks. The relationship between viral response and incidence of adverse events was analyzed. Results: Early viral response (EVR) was age- and sex-dependent, with older male patients being less responsive. Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis, b) 48-week treatment and 24-week follow-up (16 patients), and c) patients with EVR (11 patients). None of the factors was significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline in younger patients and in patients aged 50 years and older. Five of 39 (13%) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27% of patients. Conclusions: nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients. Confirmation of these data in a larger population is required.

AB - Background and Aims: We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon®) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Methods: Thirty-nine patients received a 4-week induction of 5 days/week of 6 MU nIFNα plus weight-based ribavirin followed by 3 MU of nIFNα three times a week for 44 weeks. The relationship between viral response and incidence of adverse events was analyzed. Results: Early viral response (EVR) was age- and sex-dependent, with older male patients being less responsive. Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis, b) 48-week treatment and 24-week follow-up (16 patients), and c) patients with EVR (11 patients). None of the factors was significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline in younger patients and in patients aged 50 years and older. Five of 39 (13%) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27% of patients. Conclusions: nIFNα could be a useful strategy for re-treatment in chronic hepatitis C, genotype 1, in previously nonresponsive patients. Confirmation of these data in a larger population is required.

KW - Adverse events

KW - Hepatitis C virus

KW - Natural interferon alpha

KW - Nonresponders

KW - Sustained viral response

UR - http://www.scopus.com/inward/record.url?scp=84885105897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885105897&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2013.08.004

DO - 10.1016/j.arcmed.2013.08.004

M3 - Article

VL - 44

SP - 444

EP - 448

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 6

ER -